Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 19/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.65 |
| ▸ | MC5R | P33032 | 1/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | CCNK | O75909 | 1/20 | 0.39 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25227171 | 1.00 | MC4R (0.83) | MC4RKCNH2MC5RMC3RCCNK | |
| SCHEMBL30457637 | 1.00 | MC4R (0.83) | MC4RKCNH2MC5RMC3RCCNK | |
| SCHEMBL30457504 | 1.00 | MC4R (0.83) | MC4RKCNH2MC5RMC3RCCNK | |
| SCHEMBL31687307 | 0.91 | MC4R (1.00) | MC4RKCNH2MC5RMC3R | |
| SCHEMBL31687274 | 0.91 | MC4R (0.83) | MC4RKCNH2MC5RMC3R | |
| SCHEMBL31687280 | 0.90 | MC4R (0.68) | MC4RKCNH2 | |
| Formic Acid SCHEMBL31666912 | 0.89 | MC4R (0.81) | MC4RKCNH2MC5RMC3RCCNK | |
| SCHEMBL30996498 | 0.89 | MC4R (0.67) | MC4RKCNH2CCNKCDK12 | |
| SCHEMBL31666908 | 0.88 | MC4R (0.66) | MC4RKCNH2 | |
| SCHEMBL30996497 | 0.87 | MC4R (0.86) | MC4RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444708-B1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2025-07-30 | — | — | EP | claimed |
| WO-2023105387-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-06-15 | — | — | WO | claimed |
| EP-4444708-B1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2023105387-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC2R | MC4R 1/4885KCNH2 3260/4885MC5R 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.